RT Journal Article
SR Electronic
T1 African Ancestry GWAS of Dementia in a Large Military Cohort Identifies Significant Risk Loci
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.25.22275553
DO 10.1101/2022.05.25.22275553
A1 Richard Sherva
A1 Rui Zhang
A1 Nathan Sahelijo
A1 Gyungah Jun
A1 Tori Anglin
A1 Catherine Chanfreau
A1 Kelly Cho
A1 Jennifer R. Fonda
A1 J. Michael Gaziano
A1 Kelly M. Harrington
A1 Yuk-Lam Ho
A1 William Kremen
A1 Elizabeth Litkowski
A1 Julie Lynch
A1 Zoe Neale
A1 Panos Roussos
A1 David Marra
A1 Jesse Mez
A1 Mark W. Miller
A1 David H. Salat
A1 Debby Tsuang
A1 Erika Wolf
A1 Qing Zeng
A1 Matthew S. Panizzon
A1 Victoria C. Merritt
A1 Lindsay A. Farrer
A1 Richard L. Hauger
A1 Mark W. Logue
YR 2022
UL http://medrxiv.org/content/early/2022/05/26/2022.05.25.22275553.abstract
AB We conducted the largest genome-wide association study (GWAS) of Alzheimer’s disease and related dementia (ADRD) in individuals of African-ancestry (AFR) to date using participants from the Million Veteran Program (MVP; 4,012 ADRD cases and 18,435 controls). A proxy GWAS based on survey-reported parental dementia (n=6,641 proxy cases, 45,970 controls) was also performed. The MVP AFR ADRD GWAS and proxy GWAS results were meta-analyzed and combined with the Alzheimer’s Disease Genetics Consortium’s (ADGC) AFR AD GWAS results. The MVP meta-analysis yielded genome-wide significant associations in or near APOE, ROBO1, and RP11-340A13.2. The MVP/ADGC meta-analysis yielded additional genome-wide significant variants near known risk genes TREM2, CD2AP, and ABCA7. We examined differences in expression of the implicated genes in a cohort of AD case and control brains. This study provides insight into dementia pathophysiology in historically understudied individuals of AFR and may help to address health disparities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by VA BLR&D award BX004192.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:US Department of Veterans Affairs Central Institutional Review Board protocol number 1613685-5I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUS Department of Veterans affairs restrictions do not allow the deposition of data into a public database. However, summary results will be availble on dbGAP once the study has been published. Additionally, any VA users with access to Million Veteran Program data will be able to confirm our data and results.